Technical Analysis for TRXC - TransEnterix, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical TRXC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 18 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% |
| Mar 18 | Outside Day | Range Expansion | 0.00% |
| Mar 18 | Wide Bands | Range Expansion | 0.00% |
| Mar 18 | Oversold Stochastic | Weakness | 0.00% |
| Mar 15 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.67% |
| Mar 15 | Narrow Range Bar | Range Contraction | -1.67% |
| Mar 15 | Wide Bands | Range Expansion | -1.67% |
| Mar 15 | Oversold Stochastic | Weakness | -1.67% |
| Mar 14 | 180 Bearish Setup | Bearish Swing Setup | 0.86% |
| Mar 14 | Narrow Range Bar | Range Contraction | 0.86% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-02-26
- Sector: Healthcare
- Industry: Medical Equipment, Supplies & Distribution
TransEnterix Inc, formerly SafeStitch Medical, Inc., is a developmental stage medical device company focused on the development of medical devices that manipulate tissues for the treatment of hernia formation, obesity, gastroesophageal reflux disease (GERD), esophageal obstructions, Barrett's Esophagus, upper gastrointestinal bleeding, and other intraperitoneal abnormalities through endoscopic and minimally invasive surgery. The Company's lead product candidates can also be used to treat GERD and GERD-related complications, such as Barrett's Esophagus. The Company's AMID Stapler is designed for use in open surgical repair of both inguinal (groin) and ventral (abdominal) hernias and for the approximation of tissue, including skin. In September 2013, the Company announced acquisition of TransEnterix, Inc.
Medicine Obesity Gastroenterology Minimally Invasive Surgery Esophageal Cancer Gastroesophageal Reflux Disease Medical Subject Headings
Medicine Obesity Gastroenterology Minimally Invasive Surgery Esophageal Cancer Gastroesophageal Reflux Disease Medical Subject Headings
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more TRXC news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 6.98 |
| 52 Week Low | 1.58 |
| Average Volume | 2,741,102 |
| 200-Day Moving Average | 3.8651 |
| 50-Day Moving Average | 2.65 |
| 20-Day Moving Average | 2.6125 |
| 10-Day Moving Average | 2.379 |
| Average True Range | 0.1728 |
| ADX | 16.61 |
| +DI | 15.398 |
| -DI | 24.8501 |
| Chandelier Exit (Long, 3 ATRs ) | 2.8116 |
| Chandelier Exit (Short, 3 ATRs ) | 2.7184 |
| Upper Bollinger Band | 3.2189 |
| Lower Bollinger Band | 2.0061 |
| Percent B (%b) | 0.28 |
| BandWidth | 46.422967 |
| MACD Line | -0.1089 |
| MACD Signal Line | -0.0822 |
| MACD Histogram | -0.0267 |
| Fundamentals | Value |
|---|---|
| Market Cap | 349.06 Million |
| Num Shares | 149 Million |
| EPS | -0.47 |
| Price-to-Earnings (P/E) Ratio | -5.00 |
| Price-to-Sales | 84.14 |
| Price-to-Book | 3.43 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.56 | ||||
| Resistance 3 (R3) | 2.55 | 2.48 | 2.53 | ||
| Resistance 2 (R2) | 2.48 | 2.42 | 2.48 | 2.51 | |
| Resistance 1 (R1) | 2.41 | 2.39 | 2.38 | 2.42 | 2.50 |
| Pivot Point | 2.34 | 2.34 | 2.32 | 2.34 | 2.34 |
| Support 1 (S1) | 2.27 | 2.28 | 2.24 | 2.28 | 2.20 |
| Support 2 (S2) | 2.20 | 2.25 | 2.20 | 2.19 | |
| Support 3 (S3) | 2.13 | 2.20 | 2.18 | ||
| Support 4 (S4) | 2.14 |
